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Essentials
• The roles of b-barrels 1 and 2 in factor XIII (FXIII)
are currently unknown.
• FXIII truncations lacking b-barrel 2, both b-barrels, or
full length FXIII, were made.
• Removing b-barrel 2 caused total loss of activity,
removing both b-barrels returned 30% activity.
• b-barrel 2 is necessary for exposure of the active site
cysteine during activation.
Summary. Background: Factor XIII is composed of an
activation peptide segment, a b-sandwich domain, a cat-
alytic core, and, finally, b-barrels 1 and 2. FXIII is acti-
vated following cleavage of its A-subunits by thrombin.
The resultant transglutaminase activity leads to increased
resistance of fibrin clots to fibrinolysis. Objectives: To
assess the functional roles of b-barrels 1 and 2 in FXIII,
we expressed and characterized the full-length FXIII A-
subunit (FXIII-A) and variants truncated to residue 628
(truncated to b-barrel 1 [TB1]), residue 515 (truncated to
catalytic core [TCC]), and residue 184 (truncated to b-
sandwich). Methods: Proteins were analyzed by gel elec-
trophoresis, circular dichroism, fluorometric assays, and
colorimetric activity assays, clot structure was analyzed
by turbidity measurements and confocal microscopy, and
clot formation was analyzed with a Chandler loop
system. Results and Conclusions: Circular dichroism spec-
troscopy and tryptophan fluorometry indicated that
full-length FXIII-A and the truncation variants TCC and
TB1 retain their secondary and tertiary structure.
Removal of b-barrel 2 (TB1) resulted in total loss of
transglutaminase activity, whereas the additional removal
of b-barrel 1 (TCC) restored enzymatic activity to ~ 30%
of that of full-length FXIII-A. These activity trends were
observed with physiological substrates and smaller model
substrates. Our data suggest that the b-barrel 1 domain
protects the active site cysteine in the FXIII protransglu-
taminase, whereas the b-barrel 2 domain is necessary for
exposure of the active site cysteine during activation. This
study demonstrates the importance of individual b-barrel
domains in modulating access to the FXIII active site
region.
Keywords: catalytic domain; enzyme activation; fac-
tor XIII; protein conformation; transglutaminases.
Introduction
In the final step of the blood coagulation cascade, fibrin
monomers polymerize to generate a fibrin clot. Activated
factor XIII (FXIIIa) catalyzes the formation of e-(c-glu-
tamyl)lysine covalent bonds between glutamine and lysine
residues of adjacent fibrin molecules [1]. FXIIIa is also
capable of crosslinking other substrates into the fibrin
clot network whose functions include inhibition of fibri-
nolysis (e.g. a2-antiplasmin [2,3]), increased thrombin gen-
eration at the clot surface (e.g. FV [4,5]), and platelet
adhesion to the clot (e.g. collagen [6,7]). FXIII is a 320-
kDa heterologous tetramer comprising two A-subunits,
which contain the active site of the enzyme [8], and two
B-subunits, which stabilize the hydrophobic A-subunits in
the plasma [9,10] (Fig. 1A). The A-subunits are folded
into four distinct domains, from N-terminus to C-termi-
nus: the activation peptide, b-sandwich, catalytic core
(containing the active site), b-barrel 1 and b-barrel 2
domains [8] (Fig. 1B). The dimer folds with the b-barrel
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Region of interest/protein Abbreviation Amino acids Molecular
mass (Da)
Extinction
coefficient
(mg mL–1 cm–1)
Recombinant FXIIIA rFXIII-A 1–731 (731) 83 000 1.58
Truncated to β-barrel 1 TB1 1–629 (629) 71 400 1.52
Truncated to catalytic core TCC 1–516 (516) 58 500 1.75
Truncated to β-sandwich TBS 1–184 (184) 21 400 1.4
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Fig. 1. Activation of FXIII and Factor XIIIA fragments. Schematic of activation of FXIII by thrombin and calcium (A). Recombinant full
length FXIII A subunit, TB1 (truncation to residue 628 lacking barrel 2), TCC (truncation to residue 513 lacking barrels 1 and 2), and TBS
(truncation to residue 184 lacking catalytic core, and barrels 1 and 2) were successfully produced (B & C). Schematic of FXIIIA, TB1, and
TCC (D). FXIIIA, full length FXIII A subunit; TB1, full length FXIII A subunit lacking barrel 2; TBS, full length FXIII A subunit lacking
barrels 1 and 2, and catalytic core; TCC, full length FXIII A subunit lacking barrels 1 and 2.
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domains arranged around the outside of the protein struc-
ture. Thrombin cleaves the activation peptide from the N-
terminus of each A-subunit monomer and, in the presence
of calcium, the B-subunits of FXIII dissociate from the
A-subunits, exposing the active sites of the A-subunits in
the catalytic core to substrates [11–13].
Previous studies have shown that FXIII-A2 undergoes
conformational changes upon thrombin cleavage of the
activation peptide [12,14] and in the presence of calcium
[15–17]. It is also known that fibrin enhances thrombin
cleavage of the activation peptide and contributes a bind-
ing surface for FXIII [18–22]. Fibrin thus both aids in
FXIII activation and itself serves as a transglutaminase
substrate. Although the precise changes that occur to
FXIII are not fully understood, there is strong evidence
that the b-sandwich, b-barrel 1 and b-barrel 2 all play a
role in the conformation of the catalytic core [13,23,24].
Using a recombinant FXIII-A2 truncation variant that
lacks either b-barrel 2 or both b-barrel domains, we were
able to show that b-barrels 1 and 2 are crucial for full
enzymatic activity of the protein.
Materials and methods
Production of recombinant FXIII A-subunit (FXIII-A) and
truncations
Recombinant FXIII-A was expressed in Escherichia coli
and purified as described previously [25]. Further experi-
mental details of the expression of the truncation variants
are provided in Data S1.
SDS-PAGE and densitometry analysis
Recombinant proteins were subjected to SDS-PAGE gel
analysis under reducing conditions in precast 4–12% Bis-
Tris gels (Life Technologies, Paisley, UK). Gels were
stained with Coomassie blue, and subjected to densitome-
try analysis with ID 3.1 Image software supplied with the
Kodak IS2000R Imager (Eastman Kodak Company, New
Haven, CT, USA).
Fluorometry
Fluorescence emission spectra of recombinant full-length
FXIII-A and variants truncated to residue 628 (truncated
to b-barrel 1 [TB1]) and residue 515 (truncated to cat-
alytic core [TCC]) at 1.2 lM in 10 mM 3-(N-morpholino)
propanesulfonic acid (MOPS), pH 7.4, were collected by
use of a Varioskan Flash fluorescence plate reader
(Thermo Fisher Scientific, Waltham, MA, USA) at 25 °C.
Tryptophan residues of samples were excited at 280 nm,
and emission spectra were collected in triplicate from
300 nm to 400 nm in 1-nm steps. Blanks in the absence
of proteins were measured in triplicate and subtracted
from the protein spectra. Precise sample concentrations
were determined by quantitative amino acid analysis and
spectra-compensated accordingly.
Circular dichroism (CD)
Purified full-length recombinant FXIII-A and truncations
TB1 and TCC were dialyzed into 10 mM MOPS, pH 7.4
and the concentrations were adjusted to 0.14 mg mL1.
Far-UV CD spectra were recorded in a Jasco J-715 Spec-
tropolarimeter (Jasco, Great Dunmow, UK) at 21 °C at
0.2-nm intervals over a wavelength range from 190 nm to
300 nm, in a 1-cm quartz Suprasil cuvette (Hellma,
Southend on Sea, UK). Three scans of each spectra were
averaged, baseline-subtracted against buffer, and cor-
rected to equal molar concentrations. Baseline-subtracted
spectra were zeroed between 263 nm and 270 nm. Spectra
were smoothed with the Savitsky–Golay algorithm in CD-
TOOL software [26]. Sample concentrations were deter-
mined by quantitative amino acid analysis, and spectra
were converted to mean residue ellipticity (de-
grees cm2 dmol1 residue1).
Determination of transglutaminase activity by pentylamine
incorporation
The activities of recombinant full-length FXIII-A, TB1
and TCC and a variant truncated to residue 184 (trun-
cated to b-sandwich [TBS]) were determined with a penty-
lamine incorporation assay as described previously [27].
Briefly, microtiter plates were coated with either
100 lg mL1 casein (Sigma Aldrich, Gillingham, Dorset,
UK) at 4 °C overnight or 40 lg mL1 human fibrinogen
(Enzyme Research Laboratories, Swansea, UK) at 37°C
for 1 h. After blocking with 1% bovine serum albumin
(BSA), plates were incubated with triplicates of 3.5 nM
recombinant FXIII-A sample, 0.27 lM 5-(biotinamido)
pentylamine (Thermo Fisher Scientific, Rockford, IL,
USA), 1 U mL1 human thrombin (Calbiochem, Merck,
Darmstadt, Germany), 100 lM dithiothreitol (DTT), and
1 mM CaCl2. Incorporation of 5-(biotinamido)pentyla-
mine was stopped with 133 mM EDTA over a time course
of 25 min or 120 min for the fibrinogen or casein sub-
strate, respectively. Crosslinking of the 5-(biotinamido)
pentylamine into the fibrin by recombinant FXIII was
detected by the use of streptavidin–alkaline phosphatase
(Life Technologies) and p-nitrophenyl phosphate (Sigma
Aldrich). Plates were measured at an OD of 405 nm in an
ELx808 multiwell plate reader (BioTek, Winooski, VT,
USA).
Determination of protein activity by a2-antiplasmin
incorporation
The activities of recombinant FXIII-A, TB1, TCC and
TBS were also assayed by a2-antiplasmin incorporation,
based on a method previously described [28]. Briefly,
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microtiter plates were coated with 40 lg mL1 human
fibrinogen (Enzyme Research Laboratories) at 37 °C for
1 h. After blocking with 1% BSA, plates were incubated
with 1 U mL1 human thrombin (Calbiochem) and 5 mM
CaCl2 to convert fibrinogen to fibrin, and then treated in
triplicate with 3.5 nM recombinant FXIII-A sample,
10 lg mL1 a2-antiplasmin (Calbiochem), 1 U mL
1
human thrombin, 0.1 mM DTT, and 1 mM CaCl2. Incor-
poration of a2-antiplasmin was stopped with 133 mM
EDTA over a time course of 50 min. Crosslinking of the
a2-antiplasmin into the fibrin by recombinant FXIII was
detected by the use of goat anti-human a2-antiplasmin
antibody with a horseradish peroxidase conjugate
(Enzyme Research Laboratories) and o-phenylenediamine
(OPD) (Dako, Ely, UK). Plates were measured at 490 nm
in a multiwell plate reader (ELx808; BioTek).
Determination of transglutaminase activity with a Q-
containing substrate peptide
A matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) mass spectrometry (MS) assay was
employed to monitor FXIIIa-catalyzed depletion of a
model peptide into its crosslinked product [29]. K9 pep-
tide (LGPGQSKVIG) served as the glutamine-containing
substrate, and glycine ethyl ester (GEE) as a lysine mimic.
Each reaction mix contained 220 nM FXIII-A (full length,
TB1, or TCC), 3 mM CaCl2, and 5 mM GEE, all in Tris-
acetate buffer. Bovine thrombin (7 U mL1; Sigma
Aldrich) was added and incubated at 37 °C for 5 min. K9
peptide (400 lM; Peptides International, Louisville, KY,
USA) was then added. After 5, 10 and 30 min, aliquots
were quenched with 5 mM EDTA. Samples were later run
on a MALDI-TOF mass spectrometer, and the percent-
age of reactant left at each time was calculated as
follows:
P
Reactant Peak Height  100
P
Reactant Peak HeightþPProduct Peak Height
Assays were performed in triplicate, and standard devia-
tions were calculated.
Depletion of FXIII from fibrinogen
FXIII-depleted fibrinogen was purified from human fib-
rinogen (Enzyme Research Laboratories) by ammonium
sulfate precipitation, as previously described [30].
Turbidity
Polymerization of fibrinogen in the presence of full-length
or truncated recombinant FXIII-A was measured with a
microtiter plate turbidity assay as previously described
[31]. Clots were formed in triplicate with 1 mg mL1
FXIII-depleted fibrinogen, 65 nM recombinant wild-type
FXIII-A or truncated FXIII-A, 0.125 U mL1 human
thrombin (Calbiochem), and 5 mM CaCl2. The increase in
turbidity was continually monitored at 340 nm every 12 s
in a multiwell plate reader (ELx808; BioTek) for 60 min
at 37 °C.
Confocal microscopy
Fibrinolysis rates of fibrin clots formed in the presence of
full-length or truncated recombinant FXIII-A were mea-
sured by the use of non-fluorescence confocal microscopy
as previously described [32]. Clots were formed in tripli-
cate, with the same concentrations of reactants as used
for the turbidity experiments. Lysis was then initiated
with 280 lg mL1 plasminogen (Enzyme Research Labo-
ratories) and 1 lg mL1 tissue-type plasminogen activa-
tor (t-PA) (Technoclone, Vienna, Austria). The clot was
visualized under low magnification every 20 s with a
Leica TCS SP-2 laser scanning 1072 confocal microscope
(Leica Microsystems, Heidelberg, Germany), and the time
taken for the lysis front to migrate from a fixed point was
measured. The lysis front velocity was determined and
used to calculate the mean overall lysis rate in lm s1.
Labeling fibrinogen with Alexa Fluor 488
FXIII-depleted fibrinogen was labeled with the fluo-
rophore Alexa Fluor 488 (Life Technologies). One mil-
ligram of the fluorophore was mixed with 24 mg of
FXIII-depleted fibrinogen, and incubated on a roller at
room temperature for 60 min. The unreacted fluorophore
was then removed by exhaustive dialysis into Tris-buf-
fered saline (pH 7.4). The degree of labeling was deter-
mined to be three or four molecules of dye per one
molecule of fibrinogen, according to the manufacturer’s
protocol.
Chandler loop
Fibrinolysis rates of fibrin clots formed in the presence of
FXIII-A were also measured under flow with a Chandler
loop system as previously described [32,33]. Clots were
formed by the use of FXIII-depleted fibrinogen contain-
ing 5% Alexa Fluor 488-conjugated FXIII-depleted fib-
rinogen. The same concentrations of reactants as used for
the turbidity experiments were used. After 2 h, clots were
retained within the tubing and washed with Tris-buffered
saline. Lysis was initiated with 28 lg mL1 plasminogen
(Enzyme Research Laboratories) and 0.1 lg mL1 t-PA
(Technoclone, Vienna, Austria).
Crosslinking of fibrin
Clots were formed at 37 °C by the use of 400 lg mL1
FXIII-depleted fibrinogen, 26 nM recombinant wild-type
FXIII-A or truncated FXIII-A, 0.125 U mL1 human
thrombin (Calbiochem), and 5 mM CaCl2. The reaction
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was stopped after 0, 5, 30, 60, 90 and 180 min by the
addition of reducing sample buffer (Life Technologies)
and heating the samples for 10 min at 95 °C. Samples
were run and visualized as described above.
Statistical analysis
All statistical analyses were performed with PASW 21.0
(SPSS, Chicago, IL, USA). Data are expressed as mean
and standard error of the mean. One-way ANOVA with
Bonferroni post hoc analysis was used, and P-values of
< 0.05 were considered to be statistically significant.
Results
Recombinant protein expression and structural analysis
Recombinant full-length FXIII-A, TB1, TCC and TBS
(Fig. 1B–D) were successfully expressed and purified
(Fig. 2A). Full-length recombinant FXIII-A has a kmax of
328 nm, corresponding to predominantly buried trypto-
phan side chains, in agreement with the crystal structure
(Fig. 2B; 1GGU [34]). Recombinant TB1 and TCC have
reduced fluorescence yields (areas under spectra) as a
result of the loss of three tryptophan residues located
within b-barrel 2. A kmax of 329 nm was observed with
full-length FXIII-A, TB1, and TCC, indicating that the
TB1 and TCC tryptophans are maintained in a buried
environment. As these truncation variants have identical
tryptophan locations, within the catalytic core and b-
sandwich, the similarities in kmax and fluorescence yield
suggest that their folding is highly comparable, and thus
that the enzymatically important catalytic core retains its
tertiary structure in both proteins.
CD spectroscopy was used to examine the secondary
structure of full-length recombinant FXIII-A, TB1, and
TCC. The CD spectra of recombinant FXIII-A has a neg-
ative CD signal at 215 nm, indicative of ordered sec-
ondary structure [35,36] (Fig. 2C). Both truncation
variants have increased CD signals and double minima at
208 nm and 220 nm, characteristic of an increased per-
centage of a-helical content, consistent with loss of b-
barrels 1 and 2 [35–37]. In conjunction, fluorescence and
CD spectroscopy indicated that removal of b-barrels 1
and 2 does not cause loss of secondary or tertiary struc-
ture in the remaining protein.
Recombinant protein activity
The activities of recombinant FXIII-A, TB1, TCC and
TBS were determined according to their ability to incor-
porate either a2-antiplasmin into plates coated with fib-
rinogen, or 5-(biotinamido)pentylamine into plates coated
with fibrinogen or casein (Fig. 3A). TCC (shortened to
residue 513) also showed activity, although this was
reduced to ~ 30% of that of full-length FXIII-A. TB1, in
which b-barrel 2 is eliminated, showed very little activity,
whereas TBS showed no activity, owing to the absence of
the catalytic core domain.
Determination of transglutaminase activity with a Q-
containing substrate peptide
The MALDI-TOF MS-based assay was used to assess
whether thrombin-activated recombinant FXIII-A, TB1
and TCC could covalently crosslink the lysine mimic
GEE to the glutamine-containing K9 peptide (Fig. 3B).
Over the course of the assay, the MALDI-TOF MS peak
for the K9 peptide (954 m/z) decreased in intensity over
time, whereas that for the K9 peptide–GEE product
(1040 m/z) increased. The percentage of reactant remain-
ing was then calculated. As shown in Fig. 3B,
53%  2% of K9 substrate remained after 5 min of
reaction with recombinant FXIII-A. By 30 min, only
5%  0.7% of free K9 peptide remained. TB1 and TCC,
missing one or both b-barrels, could still recognize and cat-
alyze crosslinking reactions at the active site, although with
reduced activity as compared with full-length FXIII-A.
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The results further demonstrate that the catalytic cores of
TB1 and TCC are able to accommodate a Q-containing
substrate peptide of 10 amino acids.
Clot polymerization
The effects of recombinant FXIII-A, TB1, TCC, TBS and
control (buffer only) on clot fiber thickness were investi-
gated with the turbidity technique. Only clots with full-
length FXIII-A showed a significant decrease in final
maximum absorbance as compared with control (n = 3,
P < 0.05). The final turbidity for the truncation variants
was not significantly different from that for the control
(n = 3, P > 0.05; Fig. 4A).
Clot lysis
Lysis rates of clots formed in the presence of recombinant
FXIII-A, TB1, TCC, TBS or control were investigated
with a static confocal microscopy method and under flow
in the Chandler loop. After the addition of fibrinolytic
agents to the clot, we observed a significant decrease in
the rate of fibrinolysis only for clots formed in the pres-
ence of FXIII-A as compared with control in both the
confocal microscopy (n = 3, P < 0.05; Fig. 4B) and the
Chandler loop experiments (n = 3, P < 0.05; Fig. 4C,D).
None of the truncation variants showed a significant
decrease in fibrinolysis rate with either method (n = 3,
P > 0.05; Fig. 4B–D).
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Crosslinking of fibrin
The formation of fibrin clots over time in the presence
of recombinant FXIII-A, TB1, TCC, TBS or control
was investigated on 4–12% Bis–Tris SDS-PAGE gels
under reducing conditions to determine the degree of a-
chain and c-chain crosslinking. After 30 min, 90% of the
c-chain had been incorporated into the clot formed with
full-length FXIII-A, and ~ 25% of the c-chain had been
incorporated into the clot formed with TCC, all forming
c–c dimers. The amount of unconverted c-chain
remained at 100% in the clots formed with TB1 and
TBS, relative to the control clot formed without any
FXIII (Fig. 5A,B).
Discussion
Efficient activation of FXIII is essential for the develop-
ment of a mechanically stable fibrin clot that is resistant to
lysis. The majority of this fibrinolysis resistance conferred
by FXIII is a result of the crosslinking of a2-antiplasmin to
fibrin [38]. However, the effect of FXIII on the fibrin struc-
ture itself may also contribute in part to increased resis-
tance to fibrinolysis [32]. Factors involved in the regulation
of FXIII activation include thrombin, calcium, and fibrin
[12,15,18,39–41]. However, the function of each individual
domain of the A-subunit with respect to FXIII activity has
hitherto been undetermined. In this study, we investigated
the role of the two b-barrel domains in FXIII activity.
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unit lacking barrels 1 and 2.
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Recombinant full-length FXIII-A, TCC (both b-barrels
removed) and TB1 (b-barrel 2 removed) all retained sec-
ondary and tertiary structure; thus, the b-barrels are not
required to maintain the overall, global conformations of
the catalytic core and the b-sandwich domain. Further-
more, the four FXIII domains have been reported to be
independent folding units [42]. The assays performed
showed that removal of b-barrel 2 (TB1) leads to almost
total loss of transglutaminase activity, whereas the addi-
tional removal of b-barrel 1 (TCC) returns the enzymatic
activity to ~ 30% of that of activated full-length FXIII-
A. This effect is observed not only with large, more phys-
iological substrates (fibrin, casein, and a2-antiplasmin),
but also with smaller model substrates (K9 peptide and
[biotinamido]pentylamine). Moreover, these transglutami-
nase assays made it possible to monitor the reactive glu-
tamine and the reactive lysine residues crosslinked by
activated FXIII-A. It was also important to consider the
influences on clot formation and clot lysis. Full-length
FXIII-A remained the best at supporting clot polymeriza-
tion and reducing clot lysis. Similar to the 30% enzymatic
activity mentioned above, TCC catalyzed fibrin c–c for-
mation with a reactivity that was 25% of wild-type
FXIII. Little to no fibrin c–c formation occurred with
TB1 and TBS.
FXIII contains a secondary thrombin cleavage site at the
K513–S514 peptide bond located within the C-terminal
portion of the catalytic domain [43,44]. The 51-kDa protein
that results from this cleavage has been reported to still
bind fibrin and show transglutaminase activity despite lack-
ing the two b-barrels [44,45]. Interestingly, fibrin crosslink-
ing was reduced to ~ 30% of that obtained with activated
full-length FXIII-A, consistent with the results shown here
for recombinant TCC. Lai et al. proposed that the
truncated FXIII could no longer promote effective binding
and alignment of the reactive Q and K substrates [45]. The
data on TB1 versus TCC presented in this article suggest,
for the first time, that the b-barrel 2 domain plays an
important role in maintaining the proper conformational
environment for the transglutaminase reaction. Without
the structural support of b-barrel 2, b-barrel 1 hinders
actions within the FXIII-A catalytic core domain. Prior
studies have indicated that the 19-kDa proteolytic product
(residues 514–731, b-barrels 1 and 2) is unable to bind fib-
rin [44]. This result demonstrates that the two b-barrel
domains exert their influences as part of the full FXIII-A
molecule, and not through the supporting fibrin scaffold
[44].
Solvent accessibility studies involving amide proton
hydrogen–deuterium exchange (HDX) have revealed that
both FXIII b-barrel domains participate in conforma-
tional changes occurring during both proteolytic (throm-
bin with calcium) and non-proteolytic (calcium only)
activation of FXIII [13,16,23]. The b-barrels of transglu-
taminase 2 have also been shown via HDX studies to
undergo similar alterations upon calcium-dependent
enzyme activation [46]. Members of the transglutaminase
family all have a tyrosine residue (FXIII, Y560; TG2,
Y516; and TG3, Y525) whose hydroxyl group is hydro-
gen-bonded to the thiolate group on the active site cys-
teine [24]. As part of the activation process, this tyrosine
must be displaced from the active site region, and it has
been proposed that movements of both b-barrels promote
this conformational change [24,47]. Studies involving
HDX coupled with MS have revealed that the FXIII-A
b-barrel 1 segments 533–551, 556–559 and 560–573
[48,49] become more exposed to solvent upon activation
in the presence of increasing concentrations of calcium.
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The increased exposure of FXIIII-A residues 533–573 is
consistent with this region of b-barrel 1 no longer under-
going close interactions with the catalytic core surface.
This FXIII-A segment may thus aid in displacing Y560
from the FXIII-A active site. In response, the b-barrel 2
domain could serve as a lever to help direct b-barrel 1
away from the catalytic core domain of FXIII.
Without this b-barrel 2 lever action, there may be
greater difficulties in exposing the active site C314, lead-
ing to almost no enzymatic activity. Such a loss was
observed in this study with TB1, which contains b-
barrel 1 but not b-barrel 2. With TB1, crosslinking reac-
tions involving fibrin, casein, a2-antiplasmin and model
substrates are all greatly hindered. Furthermore, the
transglutaminase effects on the rates of clot formation
and clot lysis are lost. The additional removal of b-
barrel 1 then causes enzymatic activity to return to 30%
of that of full-length FXIII-A. Once again, the different
glutamine-containing and lysine-containing substrates can
better access the catalytic core regions involved in the
transglutaminase reaction. An unresolved question is why
TCC, lacking both b-barrels, shows reduced activity rela-
tive to wild-type FXIII-A. The b-barrels may play a pro-
tective role in the zymogen form of FXIII-A. Once the b-
barrels are lost, transglutaminase activity is possible, but
the catalytic core may become more vulnerable to bio-
chemical attack at the active site or surrounding regions.
The first crystal structure of FXIII-A2 trapped in an
active conformation by a bound ligand was recently pub-
lished by Stieler et al. [50]. Ac-Asp-Michael acceptor
(MA)-Nle-Nle-Leu-Pro-Trp-Pro-OH (ZED1301) was used
as the inhibitory peptide to target FXIII. The MA group
serves as a glutamine side chain analog that attaches
covalently to the catalytic C314. FXIII-A2 was non-pro-
teolytically activated with calcium and exposed to
ZED1301 [50]. The resultant crystal structure showed the
FXIII-A2 dissociated into two monomeric A-subunits.
The FXIII b-barrel 1 and 2 domains rotated away from
the catalytic core region, and were directed upwards
towards the b-sandwich domain. The exposed FXIIIa
active site region containing the bound peptide could be
viewed for the first time. This X-ray crystal structure sup-
ports the proposed models for how TB1 and TCC work.
Without the b-barrel 2 lever, there may be difficulties in
moving b-barrel 1 into its correct position to help expose
the FXIII catalytic site region.
The FXIII truncated variants highlight the roles of the
individual b-barrel domains found within FXIII-A. The
results of this study suggest that b-barrels 1 and 2 are not
required to maintain the overall, global conformation of
the catalytic core domain. These two b-barrel domains
are, however, hypothesized to have influence on the active
site region. In the zymogen state, the b-barrel 1 domain is
proposed to protect the FXIII-A active site cysteine and
surrounding residues. Later, the b-barrel 2 domain serves
as a lever to help move b-barrel 1 away and expose the
active site. TB1 is therefore proposed to be such a poor
transglutaminase because its b-barrel 1 domain can no
longer take advantage of the lever action provided by the
b-barrel 2 domain. Transglutaminase activity is regained
with TCC, a mutant lacking both b-barrel 1 and b-
barrel 2. This study demonstrates that the individual b-
barrels play a critical role in regulating substrate access to
the FXIII active site region.
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